Houston team uses CPRIT funding to develop nanodrug for cancer immunotherapy

cancer research

Wei Gao (center), a UH assistant professor of pharmacology, and her team have developed Nano-273, which helps the immune system fight pancreatic and lung cancers. Photo courtesy UH.

With a relative five-year survival rate of 50 percent, pancreatic cancer is a diagnosis nobody wants. At 60 percent, the prognosis for lung cancer isn’t much rosier. That’s because both cancers contain regulatory B cells (Bregs), which block the body’s natural immunity, making it harder to fight the enemies within.

Newly popular immunotherapies in a category known as STING agonists may stimulate natural cancer defenses. However, they can also increase Bregs while simultaneously causing significant side effects. But Wei Gao, assistant professor of pharmacology at the University of Houston College of Pharmacy, may have a solution to that conundrum.

Gao and her team have developed Nano-273, a dual-function drug, packaged in an albumin-based particle, that boosts the immune system to help it better fight pancreatic and lung cancers. Gao’s lab recently received a $900,000 grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to aid in fueling her research into the nanodrug.

“Nano-273 both activates STING and blocks PI3Kγ—a pathway that drives Breg expansion, while albumin nanoparticles help deliver the drug directly to immune cells, reducing unwanted side effects,” Gao said in a press release. “This approach reduces harmful Bregs while boosting immune cells that attack cancer, leading to stronger and more targeted anti-tumor responses.”

In studies using models of both pancreatic and lung cancers, Nano-273 has shown great promise with low toxicity. Its best results thus far have involved using the drug in combination with immunotherapy or chemotherapy.

With the CPRIT funds, Gao and her team will be able to charge closer to clinical use with a series of important steps. Those include continuing to test Nano-273 alongside other drugs, including immune checkpoint inhibitors. Safety studies will follow, but with future patients in mind, Gao will also work toward improving her drug’s production, making sure that it’s safe and high-quality every time, so that it is eventually ready for trials.

Gao added: “If successful, this project could lead to a new type of immunotherapy that offers lasting tumor control and improved survival for patients with pancreatic and lung cancers, two diseases that urgently need better treatments."

From Your Site Articles

Here's the top innovation news to know right now. Photo via Getty Images

5 Houston suburbs among top places to retire and more innovation news

Texas institute grants $12M to bring leading cancer researchers to Houston

cha-ching

Rice University has recruited a prominent Swedish cancer researcher thanks to a $6 million grant from the Cancer Prevention and Research Institute of Texas.

It’s among $68 million in research grants recently awarded by the state agency, and six recruitment grants totaling $16 million to bring leading cancer researchers to Texas.

A news release from the Cancer Prevention and Research Institute of Texas (CPRIT) describes Pernilla Wittung-Stafshede of the Chalmers University of Technology in Gothenburg, Sweden, as “an accomplished and highly gifted biophysical scientist tackling complicated biological questions regarding the role of metals and metal dysregulation in various diseases. She pioneered a new research field around the role of metal ions in the folding and function of metalloproteins.”

Metalloproteins account for nearly half of all proteins in biology, according to the National Institutes of Health. They “catalyze some of the most difficult and yet important functions in [nature], such as photosynthesis and water oxidation,” the federal agency says.

Wittung-Stafshede, a professor of chemical biology and life sciences at Chalmers, is a former professor at Rice.

Aside from the money for Wittung-Stafshede, Houston recruitment grants also went to:

University of Texas M.D. Anderson Cancer Center: $2 million to recruit Rosalie Griffin of the Mayo Clinic
Baylor College of Medicine: $2 million to recruit Dr. Nipun Verma of the Yale University School of Medicine
Baylor College of Medicine: $2 million to recruit Xin “Daniel” Gao of Harvard University and the Massachusetts Institute of Technology

In Houston, cancer research grants were given to:

Baylor College of Medicine: $7.8 million
M.D. Anderson Cancer Center: $20.7 million
Rice University: $ 1 million
University of Houston: $1.2 million
University of Texas Health Science Center at Houston: $4.5 million

“The awards … represent the depth and diversity of CPRIT funding for cancer research in Texas,” says Kristen Doyle, CEO of CPRIT. “These grants develop new approaches to preventing, diagnosing, treating, and surviving cancer for all Texans.”

See the full list of awards here.

Here's what Houston organizations are benefitting from the latest CPRIT funding announcement. Photo via Getty Images

Houston organizations snag chunk of recently announced $49M cancer research grant funding

show me the money

Houston’s Baylor College of Medicine is beefing up its team of cancer researchers.

The college just received $6 million from the state agency Cancer Prevention and Research Institute of Texas (CPRIT) to recruit three cancer researchers: Graham Erwin, Michael Robertson and Dr. Varun Venkataramani. Each researcher is getting $2 million.

In addition, the University of Texas MD Anderson Cancer Center snagged a $2 million CPRIT grant to recruit Simon Eschweiler.

In all, CPRIT recently announced $49 million in cancer research and prevention grants, including nearly $24 million for recruitment of cancer researchers.

Here’s a rundown of the recruitment grants awarded in Houston:

Graham Erwin. Erwin is a postdoctoral fellow at Stanford University’s Stanford Cancer Institute. He’s a biologist who specializes in DNA sequencing related to the development of cancer therapeutics and diagnostics.
Michael Robertson. Robertson also is a postdoctoral fellow at Stanford. He focuses on molecular and cellular physiology at Stanford’s medical school.
Dr. Varun Venkataramani. Venkataramani, a neuroscientist, is a brain tumor researcher at University Hospital Heidelberg, one of the largest hospitals in Germany.
Simon Eschweiler. Eschweiler is a research assistant professor at Southern California’s La Jolla Institute for Immunology. He specializes in immunotherapy for cancer patients.

Aside from the recruitment grants, three institutions in the Houston area received nearly $6 million in funding for cancer treatment and prevention programs. Here’s an overview of those grants:

Almost $2.5 million for expansion of a program at the University of Texas Medical Branch at Galveston that supplies HPV vaccinations for new mothers.
Nearly $2.5 million for an MD Anderson program that promotes physical activity for cancer survivors.
Almost $500,000 for an MD Anderson program to increase treatment of tobacco users who are participating in opioid treatment programs.
Nearly $500,000 for a University of Houston program designed to help LGBTQ+ Texans lead tobacco-free lives.

“From new research programs, recruitment of preeminent scientists to Texas, pilot studies, new technology, and expanding the reach of successful cancer prevention programs, [the] grants highlight the effect CPRIT is having on not just cancer research and prevention efforts, but on life science infrastructure in Texas,” Wayne Roberts, the organization’s CEO, said in a news release.

The Cancer Prevention and Research Institute of Texas recently announced fresh funding for cancer researchers, and Houston organizations received more than 40 percent of it. Photo via Getty Images

Here's what Houston cancer researchers secured fresh funding from Texas nonprofit

grants incoming

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded around $40 million in grants to cancer researchers and cancer research institutions in the Houston area.

The Houston-area grants represent more than 40 percent of the statewide grants recently approved by Austin-based CPRIT.

The largest local grant, $6 million, went to Hongfang Liu and the University of Texas Health Science Center at Houston. The grant helped attract Liu to UTHealth Houston. She is a pioneer in biomedical informatics, an emerging field in cancer research.

Liu comes to Houston from the Mayo Clinic. At UTHealth Houston, she will be director of the Center for Translational Artificial Intelligence in Medicine within the School of Biomedical Informatics as well as vice president for learning health systems.

In a news release, Dr. Giuseppe Colasurdo, president of UTHealth Houston, says the recruitment of Lui “will strategically enhance the position of Texas as a national and international leader in data science, artificial intelligence, and informatics applications in the diagnosis, prevention, and treatment of cancer.”

Other CPRIT grant recipients at UTHealth Houston were:

Lara Savas — $2,499,492 for early detection and treatment of breast and cervical cancer among Latinas
Chao Hsing Yeh — $1,046,680 for an acupressure program to help patients manage cancer-related pain
Belinda Reininger — $999,254 for a lifestyle intervention program in South Texas
Paula Cuccaro — $449,959 for a targeted approach to boosting HPV vaccinations

What follows is a rundown of other CPRIT grant recipients in the Houston area.

University of Texas MD Anderson Cancer Center

Kenneth Hu — $2 million to recruit him as a first-time, tenure-track faculty member
Dr. Kelly Nelson — $1,998,196 to support a program for early detection of melanoma
Robert Volk — $1,988,211 for a lung cancer screening program
Jian Hu — $1.4 million for research into brain and spinal cord tumors in children
Die Zhang — $1,399,730 for research into cognitive issues caused by radiation treatment
Peng Wei — $1,199,994 for research into the evolution of bladder cancer
Boyi Gan — $1,050,000 for the study of cell death in breast cancer patients
Sue-Hwa Lin — $1,050,000 for a novel immunotherapy to treat the spread of prostate cancer to the bones
Joseph McCarty — $1,050,000 for research into invasive cells in patients with brain or spinal cord tumors
Cullen Taniguchi — $1,049,997 for the study of immune responses related to pancreatic cancer
Dr. Andrea Viale — $1,049,985 for the study of immune responses related to pancreatic cancer
Michael Curran —$1,049,905 for research into blocking DNA damage related to radiation therapy and immunotherapy
Wantong Yao — $1,049,854 for research into a novel therapy for pancreatic cancer
Eleonora Dondossola — $1,025,623 for the study of therapy resistance among certain patients with prostate or kidney cancer
Niki Zacharias Millward — $1,019,997 for the study of a type of kidney cancer that begins in the lining of small tubes inside the organ

Baylor College of Medicine

Xi Chen — $2 million for the study of immunotherapy resistance among some breast cancer patients
Melanie Bernhardt — $1,392,407 for research aimed at improving treatment of acute lymphoblastic leukemia in children
Pavel Sumazin — $1,371,733 for research into hepatocellular carcinoma, the most common type of liver cancer
Maksim Mamonkin — $1,050,000 for improving treatment of T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma

University of Texas Medical Branch at Galveston

Ana Rodriguez — $2,257,898 for an HPV vaccination program in the Rio Grande Valley

Houston Methodist Research Institute

Ewan McRae — $1,999,977 to recruit him to Houston from the United Kingdom’s Cambridge University as an expert in RNA therapeutics

University of Houston

Lorraine Reitzel — $448,726 for lung cancer screening programs

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Cancer research capabilities in the Houston area just got an $8 million boost.

On Wednesday, May 20, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded $8 million in grants to institutions in Houston and Bryan for the creation or expansion of so-called “core” cancer research facilities.

“Core facilities provide shared access to advanced technology, equipment, and scientific expertise that may not be available at every institution,” CPRIT says. “These core facilities are vital to not only cancer research but also to the study of diseases beyond cancer.”

Houston-area recipients of these $2 million grants are:

A facility at the University of Texas Health Science Center for preclinical support of cancer researchers in Texas to evaluate new safe, effective drugs and drug combinations.
The Accelerator for Cancer Therapeutics, operated by Houston’s Texas Medical Center Foundation. The accelerator helps researchers and startups move innovative cancer treatments from the lab to clinical trials.
Rice University’s Genetic Design & Engineering Center in Houston. The center enables researchers to collaborate on studies of custom DNA for cancer treatment.
A facility at the Texas A&M University System’s Health Science Center in Bryan that aims to speed up the development of cancer therapies.

In addition to those grants, the University of Texas M.D. Anderson Cancer Center, Methodist Hospital Research Institute, Baylor College of Medicine, and Rice University shared $21 million to recruit cancer researchers from other institutions.

The largest of those grants—totalling $4 million—went to M.D. Anderson for the recruitment of renowned cancer researcher Andre Nussenzweig from the National Institutes of Health. His research focuses on how DNA damage and faulty DNA repairs lead to cancer.

Here are the totals for the other CPRIT grants awarded in the Houston area:

$12.8 million to Houston-based Indapta Therapeutics for the development of an off-the-shelf therapy that naturally kills cancer cells, combined with an immunity-targeting agent for a type of leukemia.
$11.1 million to MD Anderson, including $5 million for a statewide platform to improve long-term health outcomes in adolescents and young adults who survived cancer.
$8.4 million to Baylor College of Medicine, including $4.8 million for two training programs for cancer researchers.
$6.25 million to UT Health Houston, including $4 million for a biomedical informatics and genomics training program for cancer researchers.
$4.4 million to the Texas A&M Health Science Center’s Houston campus, including $2.4 million for a cancer therapeutics training program.
$2.75 million to Rice, including $250,000 for a study of ovarian cancer.
$2 million to Houston-based March Biosciences for the development of a targeted therapy for treating T-cell lymphoma.
$1.15 million to the University of Houston, including $900,000 for a platform for detection of lung cancer.
$900,000 to Texas A&M in Bryan to conduct clinical drug trials in rural and underserved communities around the state.
$800,000 to Houston- and Israel-based Xerient Pharma for the development of an oral form of a cell-protecting drug called amifostine to protect the upper GI tract from radiation damage during pancreatic cancer treatment.
$659,000 to Missouri City-based OmniNano Pharmaceuticals for the development of a two-drug combination to treat the most common form of pancreatic cancer.
$250,000 to the University of Texas Medical Branch at Galveston for a novel therapeutic to prevent colitis-related colorectal cancer.

Axiom Space launches Japanese subsidiary, names leadership

Axiom Space is setting up a Japanese subsidiary to tap into billions of dollars worth of business opportunities in the vast Asia-Pacific region. The company’s new office in Japan will open July 1.

“For the Asia-Pacific region, an Axiom Space presence in Japan means a long-term, direct path to low-Earth orbit for research, for industry, for astronauts, and a partner committed to building that future together with Japan,” Jonathan Cirtain, president and CEO of Axiom Space, said in a news release.

Asia-Pacific spaceflight leaders include Japan, China, India and South Korea.

Until committing to the Asia-Pacific subsidiary, Axiom focused primarily on the U.S. market for space exploration equipment, technology and services. Axiom is building the successor to the International Space Station (ISS), and it provides human spaceflight services and develops next-generation spacesuits.

Fortune Business Insights estimates the Asia-Pacific market for space technology was valued at $155.3 billion in 2025.

“The region is rapidly expanding due to rapidly expanding government space programs, increasing private sector participation, and rising demand for satellite services across densely populated regions,” says Fortune Business Insights, a market research firm.

The region’s combination of strategic investments, market demand and emerging entrepreneurial systems positions Asia-Pacific “for the fastest growth in the global market,” Fortune Business Insights says.

The market research firm pegs the U.S. market for space technology at $251.8 billion in 2025, making it the world’s largest player in that sector.

Veteran Japanese astronaut Koichi Wakata will lead Axiom Space Japan as chief technology officer in the Asia-Pacific region. The Japanese subsidiary will work with government agencies, research institutions, and industrial partners in Japan to expand hardware development and manufacturing, microgravity research and orbital computing.

Wakata was the Japanese space agency’s first program manager for ISS and the station’s first Japanese commander. He also contributed to the construction of ISS, including the Japanese experiment module Kibo. Wakata retired from the Japanese agency, JAXA, in March 2024.

“Japan intends to remain a leading nation in human space exploration post-ISS, and Japanese industry and academia are ready to play a central role in the commercial era,” Axiom Space said in the release. “Axiom Space Japan is how the company will meet that ambition with a long-term, on-the-ground presence.”

Houston investment firm closes $105M energy venture fund

seeing green

Houston-based investment firm Veriten has announced the initial close of its second flagship energy venture fund with more than $105 million in capital commitments.

Fund II will build on Veriten’s initial fund and aim to support “scalable technology solutions for energy, power and industrial applications,” according to a company news release.

"Our differentiated network, research-driven process, and first principles approach to investing are having an impact across multiple verticals including traditional energy, electrification, and industrial technology. Fund II builds on that platform,” John Sommers, partner, investments at Veriten, added in the release. “In this environment, the differentiator isn't capital – it's all about connectivity, deep sector expertise, and an economically-driven approach. As new technologies and approaches develop at breakneck speed, the need for more reliable, affordable energy and power continues to grow dramatically. The current backdrop accentuates the need for Veriten's solution."

Veriten is supported by over 50 strategic partnerships in the energy, power, industrial and technology sectors, including major players like Halliburton and Phillips 66.

"Veriten continues to build a differentiated platform at the intersection of energy, technology and industry expertise," Jeff Miller, chairman and CEO of Halliburton, said in the release. "We were early believers in the team and their ability to identify practical solutions to real challenges across the energy value chain. As all industries increasingly adopt digital tools, automation and AI-enabled technologies to improve performance and execution, we are proud to partner with Veriten again to help accelerate high-impact solutions across the broader energy landscape."

Veriten closed its debut fund, NexTen LP, of $85 million in committed capital in October 2023. It was launched in January 2022 by Maynard Holt, co-founder and former CEO of the energy investment bank Tudor, Pickering, Holt & Co.

It has invested in Houston-based AI-powered electricity analytics provider Amperon and led a $12 million Seed 2 funding round for Houston-based Helix Technologies to scale manufacturing of its energy-efficient commercial HVAC add-on earlier this year. In the past year it has contributed to funding rounds for San Francisco-based Armada and Calgary-based Veerum.

Veriten also named Nick Morriss as its new managing director earlier this month. Morriss most recently served as vice president of business development at next-generation nuclear technology company Natura Resources and spent nearly 20 years at NOV Inc.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME

Houston team uses CPRIT funding to develop nanodrug for cancer immunotherapy

cancer research

1. U.S. News names 5 Houston suburbs as the best places to retire in 2026

2. 3 Houston companies land on Deloitte’s Technology Fast 500 list

3. Houston’s 10 most valuable startups revealed in new report

4. Houston scores $120M in new cancer research and prevention grants

5. Photos: Highlights from the 2025 Houston Innovation Awards

Texas institute grants $12M to bring leading cancer researchers to Houston

cha-ching

Houston organizations snag chunk of recently announced $49M cancer research grant funding

show me the money

Here's what Houston cancer researchers secured fresh funding from Texas nonprofit

grants incoming

CultureMap Emails are Awesome

4 Houston-area institutions get $8M for cancer research facilities

fighting cancer

Axiom Space launches Japanese subsidiary, names leadership

Houston investment firm closes $105M energy venture fund

seeing green

INNOVATIONMAP EMAILS ARE AWESOME

cancer research

Trending Topics

cha-ching

show me the money

grants incoming

CultureMap Emails are Awesome

fighting cancer

seeing green